@article{e14a77ac789a4656b9caa63954d08c60,
title = "Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines",
abstract = "Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.",
keywords = "Epidemiology, Monoclonal antibody, Respiratory syncytial virus, Vaccine, Vaccine impact",
author = "Lindsay Kim and Brian Rha and Abramson, {Jon S.} and Anderson, {Larry J.} and Byington, {Carrie L.} and Chen, {Grace L.} and John Devincenzo and Edwards, {Kathryn M.} and Englund, {Janet A.} and Falsey, {Ann R.} and Griffin, {Marie R.} and Karron, {Ruth A.} and Martin, {Karen G.} and Meissner, {H. Cody} and Munoz, {Flor M.} and Pavia, {Andrew T.} and Piedra, {Pedro A.} and William Schaffner and Sim{\~o}es, {Eric A.F.} and Rosalyn Singleton and Talbot, {H. Keipp} and Walsh, {Edward E.} and Zucker, {Jane R.} and Gerber, {Susan I.}",
note = "Funding Information: Potential conflicts of interest. J. S. A. has received grants from the Wake Forest School of Medicine. L. J. A. reports personal fees from AVC LLC, Moderna Therapeutics, Crucell Holland B.V., and Bavarian Nordic A/S, and holds patents for a G protein vaccine and anti–G protein mAbs for immunoprophylaxis. C. L. B. has received research funding from BioFire Intellectual Property Related and FilmArray (all monies through the University of Utah) and the National Institutes of Health (NIH), and she also has a patent related to FilmArray (BioFire Intellectual Property). J. D. reports grants from Alios Biopharma and MicroDose Therapeutx. J. A. E. reports grants and personal fees from Gilead, GlaxoSmithKline, Pfizer, Novavax, and Alios and personal fees from GlaxoSmithKline. A. R. F. has received grants from MedImmune, Sanofi Pasteur, Janssen, and Gilead, as well as personal fees from Janssen and other support from ADMA Biologics. M. R. G. has received grants from MedImmune. R. A. K. reports grants from the NIH and PATH. F. M. M. reports other support from Regeneron, Novavax, and Alios. A. T. P. has received personal fees from WebMD and other support from Janssen Pharmaceuticals, Antimicrobial Therapy Inc, and Alios Pharmaceuticals. P. A. P. reports grants from Novavax, Gilead, Regeneron, and Janssen, and personal fees from Novavax, Regeneron, MedImmune, LFB, and Ablynx. W. S. reports grants from the CDC and personal fees from Merck, Pfizer, Novavax, Dynavax, Sanofi-Pasteur, Genentech, and GlaxoSmithKline. E. A. F. S. reports grants from AstraZeneca, Regeneron, Novavax, and Pfizer. H. K. T. reports grants from MedImmune and Gilead. E. E. W. reports grants from the NIH and Gilead. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by funds from the CDC for travel of the technical consultants. Publisher Copyright: {\textcopyright} The Author 2017.",
year = "2017",
month = sep,
day = "15",
doi = "10.1093/cid/cix432",
language = "English (US)",
volume = "65",
pages = "1020--1025",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",
}